US regulators have approved a new drug, Lorbrena (lorlatibin), developed by Pfizer for the treatment of metastatic lung cancer in patients previously treated with a specific gene mutation, reports PharmaTimes.
Lorbrena is prescribed for ALK-positive metastatic non-small cell lung cancer in patients with disease progression during treatment with crizotinib and at least one ALK inhibitor, or in patients with disease progression during treatment with alectinib or ceritinib as a first-line ALK inhibitor.
The drug was approved by the accelerated procedure on the basis of data on the frequency and duration of responses from the tumor. As noted by the company, further approval may depend on the verification and description of the clinical benefits of therapy during the confirmatory study.
Lorbrena is a 3rd generation ALK tyrosine kinase inhibitor.